Breast Cancer Clinical Trial

A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer

Summary

The purpose of this study is to see if using Stereotactic Body Radiation Therapy/SBRT to treat a single metastatic site where cancer has worsened may be an effective treatment for people with oligometastatic breast cancer. Participants will stay on their usual drug therapy while they receive SBRT. This combination of SBRT to a single metastatic site and usual drug therapy may prevent participants' cancer from worsening in other metastatic sites or spreading.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Age 18 or older
Willing and able to provide informed consent

Metastatic breast cancer, biopsy proven

ER+/HER2-, defined as >5% ER+ staining
HER2+ (regardless of ER status), including HER2-low and high expressors
History of at least 6 months, sustained response to systemic therapy (clinically or radiographically defined as complete or stable response without progression)
Isolated site of disease progression on FDG PET scan
Consented to 12-245
ECOG performance status 0-1

Exclusion Criteria:

Pregnancy
Serious medical comorbidity precluding radiation, including connective tissue disorders
Intracranial disease (including previous intracranial involvement)
Previous radiotherapy to the intended treatment site that precludes developing a treatment plan that respects normal tissue tolerances.

Study is for people with:

Breast Cancer

Phase:

Phase 2

Estimated Enrollment:

40

Study ID:

NCT05534438

Recruitment Status:

Recruiting

Sponsor:

Memorial Sloan Kettering Cancer Center

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 6 Locations for this study

See Locations Near You

Memoral Sloan Kettering Basking Ridge (Limited Protocol Activities)
Basking Ridge New Jersey, 10065, United States More Info
Amy Xu, MD, PhD
Contact
646-888-6863
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
Middletown New Jersey, 07748, United States More Info
Amy Xu, MD, PhD
Contact
646-888-6863
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Montvale New Jersey, 07645, United States More Info
Amy Xu, MD, PhD
Contact
646-888-6863
Memorial Sloan Kettering Commack (Limited Protocol Activities)
Commack New York, 11725, United States More Info
Amy Xu, MD, PhD
Contact
646-888-6863
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
Harrison New York, 10604, United States More Info
Amy Xu, MD, PhD
Contact
646-888-6863
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York New York, 10065, United States More Info
Amy Xu, MD, PhD
Contact
646-888-6863
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
Uniondale New York, 11553, United States More Info
Amy Xu, MD, PhD
Contact
646-888-6863

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 2

Estimated Enrollment:

40

Study ID:

NCT05534438

Recruitment Status:

Recruiting

Sponsor:


Memorial Sloan Kettering Cancer Center

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider